Together, the combination of EZH2 inhibitors, including small molecule inhibitors of the methyltransferase activity and EZH2-specific ASO with FOXO1 nuclear localization-inducing agents such as DTX can be a viable strategy for effective treatment of cancers, especially those with PTEN loss and/or activation PI3K/AKT. Here, PTEN is linked to cancer.